Dare Bioscience (DARE) Competitors $2.41 +0.01 (+0.42%) As of 07/3/2025 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. OKYO, JSPR, FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, and SRZNShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include OKYO Pharma (OKYO), Jasper Therapeutics (JSPR), Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors OKYO Pharma Jasper Therapeutics Forte Biosciences Cellectis Climb Bio Cabaletta Bio Seres Therapeutics TScan Therapeutics VolitionRx Surrozen OKYO Pharma (NASDAQ:OKYO) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Do institutionals and insiders believe in OKYO or DARE? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 4.0% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer OKYO or DARE? In the previous week, Dare Bioscience had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Dare Bioscience and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 equaled Dare Bioscience'saverage media sentiment score. Company Overall Sentiment OKYO Pharma Neutral Dare Bioscience Neutral Which has better earnings and valuation, OKYO or DARE? Dare Bioscience has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/ADare Bioscience$10K2,124.00-$4.05M-$0.17-14.12 Which has more risk & volatility, OKYO or DARE? OKYO Pharma has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Is OKYO or DARE more profitable? Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Dare Bioscience N/A N/A -8.14% Do analysts prefer OKYO or DARE? OKYO Pharma presently has a consensus target price of $7.00, indicating a potential upside of 141.38%. Dare Bioscience has a consensus target price of $12.00, indicating a potential upside of 400.00%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryDare Bioscience beats OKYO Pharma on 6 of the 9 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.24M$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-14.1221.7127.6620.25Price / Sales2,124.00281.81415.41118.18Price / CashN/A42.7336.8958.07Price / Book-3.487.518.035.67Net Income-$4.05M-$55.14M$3.18B$249.21M7 Day Performance1.27%4.61%2.93%3.27%1 Month Performance-26.38%4.72%3.75%5.55%1 Year Performance-23.81%5.92%35.20%21.08% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience1.6139 of 5 stars$2.40flat$12.00+400.0%-22.3%$21.24M$10K-14.1230News CoverageOKYOOKYO Pharma1.8922 of 5 stars$2.57+4.9%$7.00+172.4%+145.8%$82.90MN/A0.007Positive NewsJSPRJasper Therapeutics1.894 of 5 stars$5.55+1.1%$59.25+967.6%-68.3%$82.47MN/A-1.0620Gap UpFBRXForte Biosciences2.5565 of 5 stars$12.93+5.6%$61.00+371.8%+67,596.1%$80.65MN/A-0.795CLLSCellectis3.0654 of 5 stars$1.53+5.2%$4.00+162.3%-22.7%$80.60M$49.22M-1.77290News CoverageCLYMClimb Bio2.6433 of 5 stars$1.24+5.1%$9.00+625.8%N/A$79.74MN/A-0.529Positive NewsCABACabaletta Bio1.551 of 5 stars$1.52-3.2%$14.43+849.2%-78.7%$79.67MN/A-0.6050Positive NewsGap UpMCRBSeres Therapeutics3.5627 of 5 stars$11.11+22.1%$73.67+563.1%-19.1%$79.46M$126.32M-2.42330News CoveragePositive NewsHigh Trading VolumeTCRXTScan Therapeutics1.9919 of 5 stars$1.45+3.6%$7.80+437.9%-74.2%$79.23M$2.82M-1.33100Positive NewsVNRXVolitionRx1.6967 of 5 stars$0.76-9.3%$3.50+360.5%+22.5%$78.30M$1.31M-2.1180Positive NewsGap DownSRZNSurrozen2.3965 of 5 stars$8.94-0.9%$38.50+330.6%-19.1%$77.24M$10.65M-0.3680Positive NewsHigh Trading Volume Related Companies and Tools Related Companies OKYO Pharma Alternatives Jasper Therapeutics Alternatives Forte Biosciences Alternatives Cellectis Alternatives Climb Bio Alternatives Cabaletta Bio Alternatives Seres Therapeutics Alternatives TScan Therapeutics Alternatives VolitionRx Alternatives Surrozen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DARE Stock Alerts